1. Home
  2. NYC vs KTTA Comparison

NYC vs KTTA Comparison

Compare NYC & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

HOLD

Current Price

$7.77

Market Cap

24.8M

Sector

Finance

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.51

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYC
KTTA
Founded
2013
2020
Country
United States
United States
Employees
N/A
5
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
23.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NYC
KTTA
Price
$7.77
$0.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
23.9K
417.9K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
85.28
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$0.28
52 Week High
$16.30
$2.06

Technical Indicators

Market Signals
Indicator
NYC
KTTA
Relative Strength Index (RSI) 41.16 23.73
Support Level N/A $0.28
Resistance Level $8.63 $0.76
Average True Range (ATR) 0.73 0.05
MACD -0.12 -0.01
Stochastic Oscillator 15.21 3.96

Price Performance

Historical Comparison
NYC
KTTA

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: